Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Faeth Therapeutics, Inc. (FTH : NSDQ)

• Company Description    Sensei Biotherapeutics Inc. is a clinical-stage immunotherapy company. It is focused on the discovery and development of therapeutics for cancer. The company's product pipeline includes SNS-301, SNS-401 and SNS-VISTA. Sensei Biotherapeutics Inc. is based in BOSTON, Md. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $28.29 Daily Weekly Monthly 20 Day Moving Average: 238,050 shares Shares Outstanding: 1.34 (millions) Market Capitalization: $37.96 (millions) Beta: -0.26 52 Week High: $37.90 52 Week Low: $6.33 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.67% 13.83% 12 Week 6.27% 3.36% Year To Date 165.14% 140.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1405 RESEARCH BLVD SUITE 125 - ROCKVILLE,MD 20850 USA ph: 240-243-8000 fax: - ir@senseibio.com http://www.senseibio.com

• General Corporate Information    Officers Christopher W. Gerry - Chief Executive Officer; President and General Cou Josiah Craver - Senior Vice President of Finance Bob Holmen - Director Thomas Ricks - Director Kristian Humer - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 81728A207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/04/26 Share - Related Items Shares Outstanding: 1.34 Most Recent Split Date: 6.00 (0.05:1) Beta: -0.26 Market Capitalization: $37.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.69 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-16.61 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -2,334.26% vs. Previous Quarter: -3,414.71% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - -83.59 ROA 06/30/26 - - 03/31/26 - -256.50 12/31/25 - -69.97 Current Ratio 06/30/26 - - 03/31/26 - 14.39 12/31/25 - 5.06 Quick Ratio 06/30/26 - - 03/31/26 - 14.39 12/31/25 - 5.06 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - -102.36 12/31/25 - 14.74 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - 0.00

Powered by Zacks Investment Research ©